MorphoSys to Present Clinical Trial Data on Proprietary Programs
OREANDA-NEWS. MorphoSys AG today announced the publication of three abstracts which were accepted for the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from June 3 to June 7 in Chicago, Illinois, USA. The abstracts include updated clinical data on the Company's proprietary drug candidate MOR202 from a phase 1/2a study in patients with multiple myeloma as well as a patient subgroup analysis from the phase 2 study of MOR208 in non-Hodgkin's lymphoma (NHL). The MOR202 abstract has also been selected by the conference organizers for discussion in a separate session. In addition, partners of MorphoSys will present data on several HuCAL antibodies that are currently in clinical development.
"We are delighted to publish a new package of clinical data at the preeminent conference on clinical oncology. The data set provides additional insight into the progress of our lead cancer compounds MOR208 and MOR202," commented Dr. Arndt Schottelius, Chief Development Officer of MorphoSys AG. "For MOR202, we are in particular looking forward to presenting additional efficacy data from the dose escalation Phase 1/2a study in multiple myeloma in combination with lenalidomide and with pomalidomide."
List of abstracts relating to MorphoSys's proprietary programs
MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: Data from clinically relevant cohorts from a phase 1/2a study.
The poster presentation will include safety results and, in particular, efficacy from additional patient cohorts receiving the anti CD38 antibody MOR202 alone and in combination with pomalidomide or lenalidomide from the ongoing trial. The poster presentation will take place on Monday, June 6, 8:00 am - 11:30 am CDT, as part of the Hematologic Malignancies - Plasma Cell Dyscrasia track. The findings will be discussed at the poster discussion session on Monday, June 6, 2016, 3:00 PM - 4:15 PM CDT, at E354b.
Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase 2a study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (R-R NHL).
The poster presentation will include a subgroup analysis of an open-label, multicenter, phase 2a study of the anti-CD19 antibody MOR208 in R-R NHL patients progressing after at least one prior rituximab-containing therapy, as described in the abstract. The poster presentation will take place on June 6, 8:00 am - 11:30 am CDT, as part of the Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia track.
A phase 2 study of MOR208 plus idelalisib in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) previously treated with a Bruton's tyrosine kinase inhibitor
The poster presentation will include the trial design of an intended phase 2 study (COSMOS), which was originally planned to evaluate MOR208 in combination with idelalisib in CLL and SLL, in particular ibrutinib-refractory CLL, as described in the abstract. After the discontinuation of several combination trials of idelalisib with other compounds and clinical holds by the regulatory authorities in Europe and the U.S., this planned trial is currently under review and discussions with regulatory authorities are ongoing. The poster presentation will take place on June 6, 8:00 am - 11:30 am CDT, as part of the Hematologic Malignancies - Lymphoma and Chronic Lymphocytic Leukemia track.